Cyanide Bridged Platinum-Iron Complexes as Cisplatin Prodrug Systems: Design and Computational Study

The potential role of cyanide-bridged platinum-iron complexes as an anti-cancer Pt(IV) prodrug is studied. We present design principles of a dual-function prodrug that can upon reduction dissociate and release concurrently six cisplatin units and a ferricyanide anion per prodrug unit. The prodrug molecule is a unique complex of hepta metal centers consisting of a ferricyanide core with six Pt(IV) centers each bonded to the Fe(III) core through a cyano ligand. The functionality of the prodrug is addressed through density functional theory (DFT) calculations.

Automated summary

The study examines the potential of cyanide-bridged platinum-iron complexes as an anti-cancer Pt(IV) prodrug, presenting design principles for a dual-function prodrug that can release multiple cisplatin units and a ferricyanide anion upon reduction. The unique prodrug molecule consists of a hepta metal complex with a ferricyanide core and Pt(IV) centers bonded to the Fe(III) core through cyano ligands, with the functionality of the prodrug explored through density functional theory (DFT) calculations.